Vontier Schedules Second Quarter 2025 Earnings Call
Get Alerts VNT Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.3%
Revenue Growth %: -3.0%
Join SI Premium – FREE
RALEIGH, N.C.--(BUSINESS WIRE)-- Vontier Corporation (NYSE: VNT), a leading global provider of critical technologies and solutions to connect, manage and scale the mobility ecosystem, will release its second quarter 2025 earnings results on Thursday, July 31, 2025, and will hold a conference call the same day at 8:30 a.m. ET.
The call can be accessed via webcast or by dialing +1 800-549-8228, along with the conference ID: 29924. Webcast information and related conference call materials will be made available on the “Events and Presentations” section of Vontier’s investor relations website: (www.investors.vontier.com) prior to the call.
A replay of the webcast will be available at the same location shortly after the conclusion of the presentation, or by dialing +1 888-660-6264 and passcode 29924.
ABOUT VONTIER
Vontier (NYSE: VNT) is a global industrial technology company uniting productivity, automation and multi-energy technologies to meet the needs of a rapidly evolving, more connected mobility ecosystem. Leveraging leading market positions, decades of domain expertise and unparalleled portfolio breadth, Vontier enables the way the world moves – delivering smart, safe and sustainable solutions to our customers and the planet. Vontier has a culture of continuous improvement and innovation built upon the foundation of the Vontier Business System and embraced by colleagues worldwide. Additional information about Vontier is available on the Company’s website at www.vontier.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250710129069/en/
INVESTOR RELATIONS:
Ryan Edelman
Vice President, Investor Relations
+1 (984) 238-1929
[email protected]
Source: Vontier Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
- Premarket movers: Oracle surges on AI growth, ACV auctions jumps on $1.9B deal
- MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share